ページ3 - 最高のキイトルーダ療法医師 - トップ68名の医師

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

リンパ腫と慢性リンパ性白血病の専門家として、彼と彼のチームは、血液疾患の分析とこの種の病気の新しい治療のための新技術の革新を達成しました。

ボッシュ教授は、慢性リンパ性白血病(CLL)の分野で世界的に最も評価の高い指導者の一人であり、CLLおよび他のリンパ増殖性疾患に関する臨床および基礎研究を行い、特にCLLの分子病態発生と新しい治療アプローチの開発に焦点を当てています。

ボッシュ教授は現在、フェーズ1からフェーズ3までの80以上の研究を進めており、それによりボッシュ教授の研究により、今後数年間で新しい薬剤と適応症が利用可能になることを意味しています。

教育

• 1988年にバルセロナ大学医学部を卒業。
• 1997年にバルセロナ大学で、慢性リンパ増殖性疾患におけるシグリンD1の過剰発現を研究し、イライアス・カンポ教授の指導の下で博士号を取得。
• ニューヨークのコロンビア大学がん遺伝学研究所でリッカルド・ダラ＝ファヴェラ教授の研究室で2年間の博士後研究。
• 2000年にバルセロナ・クリニック病院で慢性リンパ性白血病(LLC)の研究者。

キャリア

• 慢性リンパ性白血病の研究のためのスペイングループ（GELLC）の会長で、臨床試験分野を率いています。
• 1995年以降、CLLに関する臨床試験の開発に関与し、CLLの予後と治療の評価に多くの貢献をしています。
• 2004年からIOBオンコロジー研究所の血液学部長。
• 2009年からバルセロナのバル・デブロン大学病院の血液学部長および実験血液学研究室のディレクター。

出版物

• 「The New England Journal of Medicine」、「Nature Medicine」、「Cancer Cell」、「Blood」、「Journal of Clinical Oncology」、「Leukemia」など、権威ある科学誌に100以上の記事を発表しました。
• CLLおよび他のリンパ増殖性疾患に関するいくつかのレビューおよび書籍の章の共著者。

教育活動

バルセロナのバル・デブロン大学病院の血液学教授。

イスラエルの肺癌免疫療法の第一人者。内科、呼吸器科、腫瘍内科の専門家。

ペレッド教授は、肺癌における個別化医療と免疫腫瘍学、および疾患の診断に用いる新技術に注力している。彼はダビドフ癌センターの胸部癌ユニットの責任者であり、シーバ医療センターにおける胸部悪性腫瘍の研究と発見ユニットの責任者も務めている。2010年、ペレッド教授は米国臨床腫瘍学会（ASCO）からMERIT賞を受賞しました。

職務経験:

• シニア呼吸器科医および肺がん専門医 - ヘルツリヤ医療センター
• 2011年〜現在: 呼吸器科医・腫瘍内科医、ダビドフ癌センター、イスラエル
• 2008年〜2010年: 肺癌フェローシップ (フルブライト賞; IASLC賞; ASCO Merit賞)、コロラド大学デンバー校、米国デンバー。指導者: ポール・A・バン教授、フレッド・R・ハーシュ教授
• 2007年〜2008年: 臨床腫瘍学専門研修。ダビドフ癌センター、イスラエル
• 2005年〜2007年: 呼吸器学専門研修; ラビン医療センター、イスラエル
• 2000年〜2003年: 内科専門研修; ラビン医療センター、イスラエル
• 1999年: ベトナムでのボランティア人道ミッション
• 1994年〜1998年: IDFの医療サービス医師

会員資格:

• 欧州呼吸器学会 (ERS) の胸部腫瘍学会のメンバー
• 国際肺癌研究協会 (IASLC) の早期発見・予防委員会の議長

Deputy Head of the Department of Oncology

Chief Physician of the Oncology Center, Oncologist

セルダル・ベディ・オマイ教授は、血液学および骨髄移植の分野において65本以上の学術論文を有し、豊富な国際的研究経験を持つ。

• 日本の三重大学医学部にて博士号を取得し、血液学を専攻
• エーゲ大学およびカラデニズ工科大学にて教授職を歴任
• 当該分野における学会発表は34件以上

経歴と教育

ベイタン教授は1992年にアンカラ大学医学部を卒業し、ウルドゥグ大学医学部児童疾患学科で医学の専門家となりました。2002年には、同じ機関で小児血液学の助教授として働きました。

彼はまた、小児がん、白血病（リンパ腫）、小児出血性疾患の治療、血管閉塞、貧血治療、鉄欠乏症およびビタミン欠乏症の治療などの診断と治療に特化しています。

学術経験

ベイタン教授は、国際査読付きジャーナルに発表された15の論文、国際科学会議で発表および出版された9つの全文、地方/外国語で書かれた3つの書籍/書籍の章、地方査読付きジャーナルに公開された8つの論文を有しています。

Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.

His medical interests include:

Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)

Acute Leukemia

Chronic Leukemia Treatments

Hodgkin Lymphoma

Non-Hodgkin Lymphoma Treatments

Multiple Myeloma Treatments, MDS

Aplastic Anemia

ITP

TTP Treatments

Hypercoagulability

Hereditary Thrombophilia Treatments

Therapeutic Apheresis

Photopheresis

Geriatric Hematology Diseases.

Dr. Ahmer Arif Shaikh is an MDS (Oral & Maxillofacial Surgery) with 3 years of experience in Surgical Oncology, working at the HCG Manavata Cancer Centre - Nasik. His key takeaways include:

• Expertise in oral cancer, organ preservation and functional rehabilitation of oral cancer patients
• Interest in preventive oral hygiene & early diagnosis of oral cancers
• Proficient in performing major maxillofacial and head & neck surgeries
• Fellowship training in Head & Neck Surgical Oncology from HCG Manavata Cancer Centre, Nashik
• Researcher with many publications under his name

医師は放射線腫瘍学のMDを取得しており、コンサルタントとして勤務しています。進んだがん治療技術を専門とし、医師はトモセラピー-H、リニアアクセラレーター、ブラキセラピーを含むサービスを提供しています。これらのモダリティは、周囲の健康な組織への損傷を最小限に抑え、治療効果を高めるために正確な放射線治療を提供するために使用されます。<\/p>

医師はムンバイのTata Memorial Hospitalで外科腫瘍学の訓練を受け、エディンバラのRoyal College of SurgeonsでMRCSを修了しました。2000年に実践を開始し、2007年にCurie Manavata Cancer Centreを設立しました。19年の経験を持ち、医師は50,000件以上の癌手術を行い、200以上の臨床試験に参加しました。医師は多くの国際的および国内の出版物を持つ著者です。乳房および胸部外科腫瘍学を専門とし、医師はMUHSでDNB Superspecialty Surgical OncologyおよびBreast Surgeryの教授です。<\/p>

医師はShyam Shah Medical Collegeで内科の医学博士号を取得し、同部門でシニアレジデンシーを務めました。その後、Jawaharlal Nehru Cancer Hospitalで医療腫瘍学のレジストラとして勤務しました。医師はIndraprastha Apollo Hospitalで医療腫瘍学のDNBトレーニングを修了しました。

シニアレジデンシーの期間中、医師はAIIMSで開催されたInternational Winter School of Oncologyで講義を行い、American Society of Clinical OncologyによるGastrointestinal Cancer Symposiumで胃がんに関する研究を発表しました。医師はがんの分子基盤と標的療法を専門としています。

Dr. ラリットは、PuneのMIMERでMBBSを取得し、名門のGMC PanajiでMSを取得しました。これに続いて、彼はコルカタのタタ医療センターで2年間、外科腫瘍学のフェローシップを追求し、消化器癌に特に重点を置いたオンコサージェリーの訓練を受けました。彼はコルカタのタタ医療センターでいくつかのオリジナル研究の共同主任研究者として働きました。TMC、コルカタの後、彼は国立癌研究所およびオーランガバード政府癌病院の准教授を務めました。彼の豊富な10年間の外科経験で、彼は10,000以上の大手術を成功させました。彼は多くの国内外の出版物を持っています。彼の主な関心は、優れた結果をもたらす低侵襲癌手術にあります。彼は患者に親しみやすく倫理的なアプローチで知られています。